AGRX - Agile Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
0
0
-
-
0
Cost of Revenue
-
-
-
-
0
Gross Profit
-
-
-
-
0
Operating Expenses
Research Development
8,065
9,777
14,428
20,929
25,622
Selling General and Administrative
6,929
8,739
12,383
8,792
7,467
Total Operating Expenses
14,994
18,516
26,811
29,721
33,089
Operating Income or Loss
-14,994
-18,516
-26,811
-29,721
-33,089
Interest Expense
427
1,116
1,918
2,446
2,077
Total Other Income/Expenses Net
-
-990
143
234
-1,146
Income Before Tax
-15,755
-20,256
-28,304
-31,816
-36,307
Income Tax Expense
0
-477
0
-3,075
-5,972
Income from Continuing Operations
-15,755
-19,779
-28,304
-28,741
-30,335
Net Income
-15,755
-19,779
-28,304
-28,741
-30,335
Net Income available to common shareholders
-15,755
-19,779
-28,304
-28,741
-30,335
Reported EPS
Basic
-
-0.58
-0.91
-1.02
-1.38
Diluted
-
-0.58
-0.91
-1.02
-1.38
Weighted average shares outstanding
Basic
-
34,316
30,941
28,273
22,017
Diluted
-
34,316
30,941
28,273
22,017
EBITDA
-
-19,140
-26,363
-29,721
-33,089